高能聚焦超声联合内分泌疗法治疗前列腺癌

目的: 探讨高能聚焦超声(HIFU)联合内分泌疗法治疗前列腺癌的疗效。　方法: 对 20例前列腺癌患者行HIFU+内分泌治疗,HIFU治疗采用FEP BY01型高能聚焦超声肿瘤治疗机;内分泌治疗采用手术去势 15例,药物去势(LHRH a)5例,其中 14例加用抗雄激素药物。随访时间 6~30个月,平均16. 5个月。　结果: 治疗前后前列腺体积分别为(36. 4± 16. 2)、(20. 6±11. 8)ml(P<0. 05);血清前列腺特异性抗原值为 (32. 2±10. 4)、(2. 4±0. 8)μg/L(P<0. 01);国际前列腺症状评分为 (20. 5±6. 5)、(13. 6±7. 5 )分 (P<0. 05 );最大尿流率为 ( 10. 6±6. 3)、(14. 2±4. 6)ml/s(P<0. 05 )。HIFU治疗并发症:轻度血尿 5例,局部疼痛 8例,尿道狭窄 1例。　结论:HIFU联合内分泌疗法治疗前列腺癌并发症少,近期疗效较好。

High Intensity Focused Ultrasound Combined with Endocrine Therapy in Treating Prostate Cancer

OBJECTIVE: To evaluate the clinical efficacy of high intensity focused ultrasound (HIFU) combined with endocrine therapy in the treatment of patients with prostate cancer. METHODS: Twenty patients with prostate cancer were treated with extracorporeal HIFU device( model FEP-BY01 ) and androgen ablation, of whom 15 received orchiectomy and 5 LHRH-a. Fourteen patients of the total number were given flutamide in addition to castration. RESULTS: The mean follow-up was 13.5 months (ranging 6 to approximately 30). Before and after the treatment, the prostate volume, prostate specific antigen (PSA), international prostate symptom score (IPSS) and maximal flow rate (Qmax) of the patients were (36.4 +/- 16.2) ml and (20.6 +/- 11.8) ml (P < 0.05), (32.2 +/- 10.4) ng/ml and (2.4 +/- 0.8) ng/ml (P < 0.01), 20. 5 +/- 6.5 and 13.6 +/- 7.5 (P < 0.05), (10.6 +/- 6.3) ml/s and (14.2 +/- 4.6) ml/s (P < 0.05), respectively. Mild hematuria and pain were noted in 5 and 8 patients respectively, and 1 patient underwent internal urethrotomy with a cold knife because of urethral stricture. er, with minimal complications. CONCLUSION: HIFU combined with endocrine therapy is effective in the treatment of prostate canc-